US FDA to begin proprietary name review programme
This article was originally published in Scrip
Executive Summary
The US FDA's pilot programme for proprietary drug name reviews will allow sponsors to voluntarily evaluate a brand name for safety, as well as promotional implications, and submit the data for agency review.